based biotech, known for its lifesaving coronavirus ... $1.7 billion. Moderna emerged from the pandemic as a standout corporate winner, as its vaccine supercharged its stock price and made ...
Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth.
The phase 3 results bolster Moderna’s combination products, namely a lead COVID-flu combo vaccine that uses mRNA-1283. CEO Stephane Bancel said the data reinforce “confidence in our ability to ...
Pfizer Inc. and Moderna Inc. have raised the prices of their COVID-19 vaccines in their latest European Union supply contracts, the Financial Times reported on Sunday. The new price for the Pfizer ...
Moderna (NASDAQ:MRNA) is obviously best known as a vaccine company, with much of its success in recent years owed to their COVID-19 vaccines. Of course, this isn't the only story they're working ...
It also had plans to start filling doses of its COVID vaccine in the continent as early as 2023. However, Moderna has not received ... Financecategory JPMorgan CEO Dimon sells about $33 mln ...
Covid vaccines from companies like Pfizer, Moderna and AstraZeneca were linked to rare occurrences of heart, brain and blood ...
The Moderna (Nasdaq: MRNA) CEO’s compensation last year included a base salary of about $1.56 million, which was actually an increase ... vaccine-maker. The company saw a drop in interest in ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. US biotech Moderna has put plans to build a vaccine plant in Kenya on hold, in a sign that moves to invest ...
LONDON: Pfizer Inc and Moderna Inc have raised the prices of their COVID-19 vaccines in their latest European Union supply contracts, the Financial Times reported ...